GENE ONLINE|News &
Opinion
Blog

2025-02-11| APAC

South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate

by Bernice Lottering
Share To
OliX Pharmaceuticals partners with Eli Lilly on MASH treatment, securing a $660M deal to develop OLX75016 for metabolic diseases.
OliX Pharmaceuticals (KOSDAQ: 226950), a leading developer of RNA interference (RNAi) therapeutics, has entered into a global licensing agreement with Eli Lilly and Company (Lilly) …

South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate Read More »

GO Prime with only $1.49 now

SUBSCRIBE NOW
LATEST
WCC BIOMEDICAL Overcomes Microneedle Array Patches Manufacturing Challenges, Advancing Next-Generation Drug Delivery
2026-07-18
Geometric Constraints in Crop Breeding Explain Slowing Genetic Progress
2026-07-17
Texas Tech Veterinary Students Publish Independent Research on Equine Genomics and Veterinary Science
2026-07-17
UVA Professor Geoff Geise Receives NAMS Permeance Prize for Membrane Research
2026-07-17
American Heart Association Awards Grants to 164 Schools Following 30 Percent Rise in Youth Obesity Rates
2026-07-17
American Heart Association Provides Hands-Only CPR Training at 2026 MLB All-Star Game
2026-07-17
Yale Study Finds Tuna Evolution Occurred Independently of Asteroid Impact
2026-07-17
READ MORE
EVENT
2026-07-15
BIO Asia-Taiwan 2026 (APAC Biotech & Investment)
Taipei, Taiwan
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
2026-09-02
BIO Asia Pacific (APAC Biotech & Smart Health)
Bangkok, Thailand
2026-09-16
BIOHK (16–19, Hong Kong) (Hong Kong biotech & investment)
Hong Kong
2026-10-07
BioJapan / HealthTECH JAPAN (Biotech, Medtech, Regenerative)
Yokohama, Japan
2026-10-07
Hospital Expo Tokyo (Devices & Hospital IT)
Tokyo, Japan
SEE MORE
Scroll to Top